Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03871439 · ClinicalTrials.gov registry record · Phase 1
Open Label, 2-period Study, TO Compare Bio-availability OF 2 Different Formulations OF PF-05221304 IN Healthy Adults
A Phase 1 study, sponsored by Pfizer.
- Completed
- Registry status
- Phase 1
- Development phase
- 10
- Enrollment target
NCT03871439 is a Phase 1 study that has completed, run by Pfizer. The registered enrollment target is 10 participants.
The verdict
NCT03871439, a Phase 1 study, has completed, sponsored by Pfizer.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 10 participants
- Enrollment target
Study Summary
The purpose of this study is to characterize the plasma pharmacokinetics of two formulations of PF 05221304 in healthy adults.
Interventions
- DRUG PF-05221304 Formulation A
- DRUG PF-05221304 Formulation B
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 10 participants |
| Start Date | 2019-03-13 |
| Est. Completion | 2019-05-08 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03871439
The ClinicalTrials.gov registry entry for NCT03871439 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 10 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Pfizer, which has 1,845 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which PF-05221304 Formulation A is the first listed.
NCT03871439 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03871439 about?
NCT03871439 is a clinical study titled "Open Label, 2-period Study, TO Compare Bio-availability OF 2 Different Formulations OF PF-05221304 IN Healthy Adults". The purpose of this study is to characterize the plasma pharmacokinetics of two formulations of PF 05221304 in healthy adults.
What is the current status of trial NCT03871439?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 10 participants. The study started on 2019-03-13. Estimated completion is 2019-05-08.
What interventions are being tested in trial NCT03871439?
The interventions under investigation include: PF-05221304 Formulation A (DRUG), PF-05221304 Formulation B (DRUG).
Who is sponsoring clinical trial NCT03871439?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.